DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ:LENS), an ophthalmic device company and leader in near-vision restoration, will participate in the XXXVI Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), Europe's leading organization for cataract and refractive surgeons, to be held in Vienna, Austria from September 22-26, 2018.
“We have made significant progress in 2018, including our submission in the second quarter of 2018 to the U.S. Food and Drug Administration of our Premarket approval containing 24-month data on our Investigational Device Exemption subjects,” said Mark Yung, Chairman and CEO of Presbia. “Participating in ESCRS supports the commercialization efforts of our Microlens in Germany.”
Mr. Yung will be available for one-on-one meetings at booth number B200 during the ESCRS.
Presbia will also participate in the German Ophthalmological Society Congress to be held in Bonn, Germany from September 27-29, 2018. The German Ophthalmological Society is the medical scientific association of ophthalmology in Germany, uniting physicians and scientists in treatment and research in ophthalmology.
Presbia representatives will be available at booth number K.54 during the German Ophthalmological Society Congress to answer any questions.
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2017, quarterly reports on Form 10-Q, and other reports that Presbia files with the SEC. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.